Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» osteoporosis
osteoporosis
Radius plans to cut loose oncology assets
Radius plans to cut loose oncology assets
Fierce Biotech
Radius
oncology
cancer
endocrine disorders
osteoporosis
Flag link:
Merck seeks partner for disease-modifying osteoarthritis drug
Merck seeks partner for disease-modifying osteoarthritis drug
PM Live
Merck KGaA
osteoporosis
sprifermin
Flag link:
FDA approves Pfenex's osteoporosis therapy
FDA approves Pfenex's osteoporosis therapy
Yahoo/Reuters
Pfenex
osteoporosis
PF708
FDA
Eli Lilly
Forteo
Flag link:
Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe
Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe
Pharmaforum
Eli Lilly
biosimilars
osteoporosis
Forsteo
Europe
Stada
Gedeon Richter
Flag link:
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis
Pharmaceutical Business Review
Novartis
Sandoz
biosimilars
clinical trials
denosumab
osteoporosis
Prolia
Xgeva
Flag link:
Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug
Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug
Endpoints
Amgen
UCB Pharma
FDA
EMA
Europe
osteoporosis
Evenity
romosozumab
Flag link:
Consumer watchdog petitions FDA for black box warning on Amgen's Prolia
Consumer watchdog petitions FDA for black box warning on Amgen's Prolia
Fierce Pharma
FDA
osteoporosis
Amgen
Prolia
spinal fractures
Public Citizen
Flag link:
Amgen prices bone builder Evenity at $21,900/year to compete on convenience, not cost
Amgen prices bone builder Evenity at $21,900/year to compete on convenience, not cost
Endpoints
Amgen
osteoporosis
Evenity
drug pricing
Flag link:
FDA approves Evenity for osteoporosis
FDA approves Evenity for osteoporosis
BioCentury
FDA
Evenity
romosozumab
Amgen
UCB Pharma
osteoporosis
Flag link:
Amgen's once-dismissed osteoporosis drug Evenity 'back in the game' after rosy FDA panel vote
Amgen's once-dismissed osteoporosis drug Evenity 'back in the game' after rosy FDA panel vote
Fierce Pharma
Amgen
osteoporosis
Evenity
romosozumab
FDA
advisory panels
Flag link:
FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials
FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials
Endpoints
Amgen
osteoporosis
FDA
romosozumab
clinical trials
Flag link:
Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA — but big hurdles lie ahead
Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA — but big hurdles lie ahead
Endpoints
Amgen
UCB Pharma
osteoporosis
romosozumab
Flag link:
Radius Health Initiates Phase III Trial of Osteoporosis Injection Drug for Males
Radius Health Initiates Phase III Trial of Osteoporosis Injection Drug for Males
CP Wire
Radius Health
osteoporosis
men's health
Tymlos
clinical trials
Flag link:
Amgen rolls new Prolia osteoporosis ads, just weeks after next-gen Evenity hits a snag
Amgen rolls new Prolia osteoporosis ads, just weeks after next-gen Evenity hits a snag
Fierce Pharma
Amgen
Prolia
osteoporosis
drug ads
Flag link:
Payer coverage boosts Radius' Tymlos
Payer coverage boosts Radius' Tymlos
BioPharma Dive
Radius Health
Tymlos
PBMs
Express Scripts
osteoporosis
Flag link:
Radius' Tymlos gets another big break as Express Scripts boots Lilly's Forteo
Radius' Tymlos gets another big break as Express Scripts boots Lilly's Forteo
Fierce Pharma
Radius Health
Tymlos
Express Scripts
PBMs
formulary
Eli Lilly
Forteo
osteoporosis
Flag link:
An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis Landscape
An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis Landscape
Seeking Alpha
Amgen
Radius Health
osteoporosis
Tymlos
romosozumab
Flag link:
FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
Endpoints
FDA
Amgen
osteoporosis
romosozumab
UCB Pharma
Radius Health
Tymlos
Flag link:
Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug
Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug
Fierce Pharma
Amgen
romosozumab
Radius Health
UCB Pharma
Tymlos
osteoporosis
Flag link:
With Amgen hot on its heels, Radius races to get a jump on osteoporosis drug rivalry
With Amgen hot on its heels, Radius races to get a jump on osteoporosis drug rivalry
Endpoints
Amgen
Radius Health
osteoporosis
Tymlos
romosozumab
Flag link:
Pages
1
2
3
4
5
6
7
8
next ›
last »